Autoimmunity

6.
Therapeutic Strategies and Management
6.2.
Pharmacological Interventions
6.2.2.
Conventional Disease-Modifying Antirheumatic Drugs
6.2.2.6.
Cyclophosphamide
6.2.2.6.3.
Administration
6.2.2.6.3.1.
Oral
6.2.2.6.3.2.
Intravenous Pulse
6.2.2.6.4.
Side Effects
6.2.2.6.4.3.
Gonadal Toxicity
6.2.2.6.4.4.
Malignancy Risk
6.2.2.6.5.
Monitoring
6.2.2.6.5.2.
Urinalysis
6.2.3.
Biologic Therapies
6.2.3.2.
B Cell-Targeting Therapies
6.2.3.2.1.
Rituximab
6.2.3.2.1.1.
Mechanism of Action
6.2.3.2.1.1.1.
CD20 Targeting
6.2.3.2.1.1.2.
B Cell Depletion
6.2.3.2.2.
Belimumab
6.2.3.2.2.2.
Indications
6.2.3.2.2.3.
Side Effects
6.2.3.2.2.3.1.
Infectious Risk
6.2.3.2.2.3.2.
Depression Risk
6.2.3.3.
T Cell Costimulation Blockers
6.2.3.3.1.
Abatacept
6.2.3.3.1.2.
Indications
6.2.3.3.1.2.1.
Rheumatoid Arthritis
6.2.3.3.1.2.2.
Psoriatic Arthritis
6.2.3.3.1.3.
Side Effects
6.2.3.3.1.3.1.
Infectious Risk
6.2.3.3.1.3.2.
Malignancy Risk
6.2.3.4.
Interleukin Inhibitors
6.2.3.4.1.
IL-6 Receptor Antagonists
6.2.3.4.1.1.
Tocilizumab
6.2.3.4.1.1.1.
Mechanism of Action
6.2.3.4.1.1.2.
Indications
6.2.3.4.1.1.3.
Side Effects
6.2.3.4.1.2.
Sarilumab
6.2.3.4.2.
IL-17 Inhibitors
6.2.3.4.2.1.
Secukinumab
6.2.3.4.2.2.
Ixekizumab
6.2.3.4.2.3.
Brodalumab
6.2.3.4.3.
IL-23 Inhibitors
6.2.3.4.3.1.
Ustekinumab
6.2.3.4.3.2.
Guselkumab
6.2.3.4.3.3.
Risankizumab
6.2.3.4.4.
IL-1 Inhibitors
6.2.3.4.4.1.
Anakinra
6.2.3.4.4.2.
Canakinumab
6.3.
Non-Pharmacological Interventions

Previous

5. Diagnosis and Clinical Evaluation

Go to top

Next

7. Research Frontiers and Future Directions